Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.53 |
| ▸ | GRB2 | P62993 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | NPY4R | P50391 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14060524 | 0.94 | BACE1 (0.52) | KISS1RBACE1ACENPY1RNPY2R | |
| SCHEMBL30546676 | 0.92 | BACE1 (0.51) | KISS1RBACE1ACENPY1RNPY2R | |
| SCHEMBL29624265 | 0.89 | KISS1R (0.52) | KISS1RGRB2BACE1ACE | |
| SCHEMBL31556395 | 0.89 | ACE (0.53) | KISS1RBACE1ACENPY1RNPY2R | |
| SCHEMBL30433557 | 0.86 | KISS1R (0.54) | KISS1RBACE1NPY1RNPY2RNPY4R | |
| SCHEMBL31556390 | 0.85 | NTSR1 (0.56) | OXTRNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29413128 | 0.85 | KISS1R (0.51) | KISS1RGRB2BACE1OXTR | |
| SCHEMBL29496659 | 0.85 | NTSR1 (0.56) | OXTRNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31278149 | 0.84 | ACE (0.53) | BACE1ACEBACE2 | |
| SCHEMBL31690551 | 0.84 | KISS1R (0.56) | KISS1RBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414459-B2 | Metabolite inspired selective oxytocin receptor agonists | Kinoxis Therapeutics Pty Ltd (AU) | 2022-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414459-B2 | Metabolite inspired selective oxytocin receptor agonists | OXTR, AVPR2, AVPR1A | KISS1R 20/4885GRB2 1169/4885BACE1 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.